Pharvaris (PHVS) Consolidated Net Income (2020 - 2026)
Pharvaris (PHVS) posted Consolidated Net Income of -$45.3 million for Q1 2026, up 10.45% on a QoQ basis from -$50.5 million in Q4 2025, and up 5.93% year-over-year from -$42.7 million in Q1 2025.
Pharvaris (PHVS) Consolidated Net Income (2020 - 2026) Analysis & Trends
Pharvaris' Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$45.3 million for Q1 2026.
- Quarterly Consolidated Net Income rose 5.93% year-over-year to -$45.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$190.7 million (down 19.33% YoY) and the FY2025 annual result came in at -$194.0 million, down 37.29% from the prior year.
- Consolidated Net Income was -$45.3 million for Q1 2026 at Pharvaris, up from -$50.5 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$7.6 million in Q2 2022 and bottomed at -$51.0 million in Q2 2025.
- A 5-year average of -$33.6 million and a median of -$34.5 million in 2024 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income surged 58.38% — and 2023, when it plunged 210.34%.
- Pharvaris' Consolidated Net Income stood at -$41.5 million in 2022, then advanced by 10.71% to -$37.0 million in 2023, then climbed by 6.79% to -$34.5 million in 2024, then plunged by 46.49% to -$50.5 million in 2025, then climbed by 10.45% to -$45.3 million in 2026.
- Business Quant data shows PHVS's Consolidated Net Income at -$45.3 million in Q1 2026, -$50.5 million in Q4 2025, and -$43.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Pharvaris | 2.17 Bn | 1.88 Bn | - | -45.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.25 Mn |
| Dec 31, 2025 | -50.53 Mn |
| Sep 30, 2025 | -43.84 Mn |
| Jun 30, 2025 | -51.02 Mn |
| Mar 31, 2025 | -48.11 Mn |
| Dec 31, 2024 | -34.50 Mn |
| Sep 30, 2024 | -45.30 Mn |
| Jun 30, 2024 | -31.86 Mn |
| Mar 31, 2024 | -29.82 Mn |
| Dec 31, 2023 | -37.01 Mn |
| Sep 30, 2023 | -25.37 Mn |
| Jun 30, 2023 | -23.64 Mn |
| Mar 31, 2023 | -24.16 Mn |
| Dec 31, 2022 | -41.45 Mn |
| Sep 30, 2022 | -13.41 Mn |
| Jun 30, 2022 | -7.62 Mn |
| Mar 31, 2022 | -17.90 Mn |
| Dec 31, 2021 | 34,559.40 Bn |
| Sep 30, 2021 | -10.62 Mn |
| Jun 30, 2021 | -18.30 Mn |